

**AMENDMENTS TO THE CLAIMS**

Please amend the claims as follows:

1. (Original) An ischemia therapeutic agent that contains vascularization induction factor and gelatin hydrogen, and gradually releases vascularization growth factor.
2. (Currently Amended) An ischemia therapeutic agent according to claim 1, wherein the gelatin has the following physical properties:
  - (1) an acidic gelatin obtained from collagen by alkaline hydrolysis treatment;
  - (2) molecular weight under non-reducing conditions of SDS-PAGE of about 100,000 to about 200,000 daltons; and,
  - (3) zeta potential in aqueous solution of about -15 to about -20 mV.
3. (Currently Amended) An ischemia therapeutic agent according to claim 1, or 2 wherein the vascularization induction factor is selected from the group consisting of basic fibroblast growth factor, vascular endothelial growth factor and hepatocyte growth factor.
4. (Currently Amended) An ischemia therapeutic agent according to ~~any of the~~ claim[[s]] 1, to 3 wherein the ischemia accompanies a disease selected from the group consisting of atherosclerosis obliterans, Buerger's disease and poor peripheral circulation occurring as a complication of diabetes or collagen disease.
5. (Currently Amended) An ischemia therapeutic agent according to ~~any of~~ claim[[s]] 1, to 4 wherein the ischemia is ischemia in the upper or lower extremities.
6. (New) An ischemia therapeutic agent according to claim 2, wherein the vascularization induction factor is selected from the group consisting of basic fibroblast growth factor, vascular endothelial growth factor and hepatocyte growth factor.
7. (New) An ischemia therapeutic agent according to claim 2, wherein the ischemia accompanies a disease selected from the group consisting of atherosclerosis obliterans, Buerger's disease and poor peripheral circulation occurring as a complication of diabetes or collagen disease.

8. (New) An ischemia therapeutic agent according to claim 3, wherein the ischemia accompanies a disease selected from the group consisting of atherosclerosis obliterans, Buerger's disease and poor peripheral circulation occurring as a complication of diabetes or collagen disease.
9. (New) An ischemia therapeutic agent according to claim 6, wherein the ischemia accompanies a disease selected from the group consisting of atherosclerosis obliterans, Buerger's disease and poor peripheral circulation occurring as a complication of diabetes or collagen disease.
10. (New) An ischemia therapeutic agent according to claim 2, wherein the ischemia is ischemia in the upper or lower extremities.
11. (New) An ischemia therapeutic agent according to claim 3, wherein the ischemia is ischemia in the upper or lower extremities.
12. (New) An ischemia therapeutic agent according to claim 6, wherein the ischemia is ischemia in the upper or lower extremities.
13. (New) An ischemia therapeutic agent according to claim 4, wherein the ischemia is ischemia in the upper or lower extremities.
14. (New) An ischemia therapeutic agent according to claim 7, wherein the ischemia is ischemia in the upper or lower extremities.
15. (New) An ischemia therapeutic agent according to claim 8, wherein the ischemia is ischemia in the upper or lower extremities.
16. (New) An ischemia therapeutic agent according to claim 9, wherein the ischemia is ischemia in the upper or lower extremities.